Causes and Risk Factors of Muscle Atrophy

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative

Introduction

Muscle atrophy occurs when muscles waste away, either partially or completely, due to the degeneration of muscle cells. The primary causes of muscle wasting include lack of physical activity, nutritional deficiencies, and genetic factors. This condition can arise when disease or injury makes it difficult or impossible to move a body part, such as an arm.

Muscle atrophy results from an imbalance between protein synthesis and degradation, with the latter exceeding the former. Since this condition can significantly impact the quality of life, understanding the mechanisms and factors that contribute to atrophy is crucial for developing effective prevention and management strategies.1

Types of muscle atrophy

Muscle atrophy can occur due to a variety of underlying causes, each leading to different forms of muscle wasting. Some of the most common types include:

Disuse atrophy

This type occurs when muscles are not used for prolonged periods, often due to immobility from bed rest, casting, or a sedentary lifestyle. Without regular movement or exercise, muscle fibres shrink and weaken over time.

Neurogenic atrophy

Resulting from damage to the nerves that control muscles, neurogenic atrophy can be caused by conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), spinal cord injury, or peripheral neuropathies. This type of atrophy is often more severe because it directly impacts the nervous system's ability to stimulate muscle function.

Cachexia

Often associated with chronic diseases like cancer, HIV/AIDS, and heart failure, cachexia leads to significant muscle wasting due to systemic inflammation and metabolic changes, making it difficult for the body to maintain muscle mass even with adequate nutrition.

Sarcopenia 

A natural part of the ageing process, sarcopenia involves the gradual loss of muscle mass and strength, which can affect mobility and overall physical function in older adults.

Other medical conditions

Muscle atrophy can also be triggered by hormonal imbalances (such as hyperthyroidism or Cushing's syndrome), inflammatory conditions like rheumatoid arthritis, or malnutrition and nutrient deficiencies, all of which can disrupt the body’s ability to maintain healthy muscle tissue.

Primary causes of muscle atrophy

The cause of muscle atrophy depends on the type of atrophy one has, which can be either physiological or neurogenic. 

Physiological atrophy is when the muscles are not used enough, leading to their breakdown, weakening, and eventual decrease in size. This can be due to the following:

  • Malnourishment 
  • Sedentary lifestyle
  • Lack of exercise 
  • Having a desk job
  • Genetic disorders such as muscular dystrophy, Charcot-Marie-Tooth disease or spinal muscular atrophy, which happens on chromosome 5 where the genes in SMN1 are mutated, leading to a deficiency of the survival motor neuron protein
  • Stroke, which can render limbs immobile
  • Sarcopenia (age-related atrophy)3

Neurogenic atrophy occurs when nerves that connect to muscles are damaged. The nerve damage prevents muscle contractions, leading to the breakdown of these muscles as the body thinks they are no longer needed. This can be due to the following: 

Risk factors for muscle atrophy

Several factors can increase the likelihood of developing muscle atrophy, including genetic, lifestyle, and medical influences. By addressing these risk factors through targeted interventions like physical activity, proper nutrition, and medical management, the progression of muscle atrophy can often be slowed or mitigated.

Genetic predisposition

Genetic factors can influence the body’s ability to maintain muscle mass, making some individuals more susceptible to muscle atrophy. Inherited conditions or genetic mutations that affect muscle metabolism or function may predispose individuals to conditions like sarcopenia or neurogenic atrophy earlier in life.

Age

As people age, the body’s ability to repair and regenerate muscle tissue decreases, leading to a gradual loss of muscle mass and strength. This age-related decline in muscle function, known as sarcopenia, can significantly impact mobility and overall quality of life if not managed through proper exercise and nutrition.

Lifestyle factors

Physical inactivity is one of the most important factors that cause muscle atrophy. Prolonged periods of inactivity, such as sedentary behaviour or bed rest, can lead to muscle loss over time. Inadequate intake of protein and essential nutrients can furthermore impair muscle repair and growth, accelerating atrophy.

Medical history

Previous injuries or surgeries that result in extended immobility can lead to muscle degradation due to disuse, while chronic illnesses such as diabetes and chronic obstructive pulmonary disease (COPD) contribute to muscle atrophy through systemic inflammation and metabolic changes.5

Mechanisms underlying muscle atrophy

Muscle atrophy occurs when the balance between muscle protein synthesis and degradation is disrupted, leading to a loss of muscle mass. Understanding the underlying mechanisms is crucial for developing effective strategies to prevent or reverse muscle atrophy in various conditions.

Protein degradation pathways

Ubiquitin-proteasome system

The proteasome is a cellular machine that breaks down proteins into smaller pieces. The process, termed proteolysis, helps the body get rid of damaged or unnecessary proteins. Proteolysis is highly regulated, as dysfunction can cause disease. Protein undergoes several steps before being degraded by the proteasome. 

The ubiquitin-proteasome system (UPS) is a crucial cellular mechanism for maintaining healthy cells. It involves tagging damaged or unneeded proteins with ubiquitin, a small regulatory protein.6 This tag signals that the protein should be destroyed. The system involves attaching ubiquitin to the target protein, which marks it for breakdown by the proteasome. Ubiquitin attaches to the protein at a specific spot, forming a special bond that leads to the protein’s destruction. This attachment process involves three key enzymes, known as E1, E2, and E3.7

To summarize and oversimplify the process: First, the protein is modified through a process called ubiquitination, which tags it for destruction. It is then unfolded and chopped up into short polypeptides by the proteasome. Once the proteasome releases the short polypeptides, they get further broken down into their amino acid building blocks by other enzymes called proteases.7

Autophagy-lysosome pathway

Autophagy is the cell's natural and regulated process for eliminating unnecessary or dysfunctional components. This mechanism enables the systematic breakdown and recycling of cellular materials. There are three commonly recognised types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy. ​​In macroautophagy, double-membrane vesicles called autophagosomes deliver damaged proteins and organelles to the lysosome for degradation.

In microautophagy, material is delivered to the lysosome via vesicles, but in a slightly more direct manner, using vesicles formed from inward folding of the lysosomal membrane. Chaperone-mediated autophagy (CMA) does not use vesicles but instead uses special proteins called chaperones to guide specific proteins directly to the lysosome for breakdown.8

Cytokines inflammatory response

Cytokines are tiny proteins secreted by both immune and non-immune cells to communicate with one another. They attach to specific receptors on target cells and initiate a response. Cytokines facilitate the activation, proliferation, and differentiation of immune cells, and can also perform other functions, such as raising body temperature to induce a fever.

Cytokines signal to other cells mainly through autocrine and paracrine signalling, with a lesser extent of endocrine signalling also being used. In autocrine signalling, the cell producing the cytokine is also the one responding to it.

Diagnostic approaches

Clinicians use various methods to diagnose muscle atrophy. Diagnostic approaches include:10

  • Clinical assessment
  • Imaging techniques (e.g. MRI, CT scans)
  • Muscle/nerve biopsy
  • Electromyography (EMG)
  • Nerve conduction studies
  • Laboratory tests (e.g. Blood tests for inflammatory markers)

Prevention and management strategies

Preventing muscle atrophy involves a combination of proactive strategies. Regular exercise and physical therapy, including targeted stretches and strengthening exercises, can effectively prevent muscle loss. Nutritional interventions, such as protein supplementation and a well-balanced diet rich in essential vitamins and minerals, support muscle maintenance and recovery. In some cases, medical treatments like anabolic steroids or anti-inflammatory drugs may be prescribed to aid in preserving muscle mass.

FAQs

How long does it take to recover from muscle atrophy?

Recovery is dependent on the type and severity of muscle atrophy. This can often be done by regular exercise and maintaining a healthy diet. It may take a few months to see noticeable changes, and even longer to regain full muscle strength. 

Are muscle loss and muscle atrophy the same?

Yes, muscle loss and muscle atrophy refer to the same condition. "Muscle atrophy" is just another term for muscle loss.

Summary

Muscle atrophy, or muscle loss, often occurs gradually and can be due to various factors including age, nutrition, genetics, and even certain medical conditions such as rheumatoid arthritis. Muscle atrophy can significantly impact an individual's daily life, reducing the overall quality of life. Treatment is dependent on the type and severity of atrophy, but it is always recommended to see a doctor if muscle loss is suspected. Treatments typically involve a combination of exercises, physical therapy, and dietary changes.

References

  1. Cao RY, Li J, Dai Q, Li Q, Yang J. Muscle atrophy: present and future. In: Xiao J, editor. Muscle Atrophy [Internet]. Singapore: Springer Singapore; 2018 [cited 2024 Jun 27]. p. 605–24. Available from: http://link.springer.com/10.1007/978-981-13-1435-3_29
  2. Cleveland Clinic [Internet]. [cited 2024 Jun 27]. Muscle atrophy: causes, symptoms & treatment. Available from: https://my.clevelandclinic.org/health/diseases/22310-muscle-atrophy
  3. Zizzo J. Muscle atrophy classification: the need for a pathway-driven approach. CPD [Internet]. 2021 Sep 17 [cited 2024 Jun 27];27(27):3012–9. Available from: https://www.eurekaselect.com/192293/article
  4. Ehmsen JT, Höke A. Cellular and molecular features of neurogenic skeletal muscle atrophy. Experimental Neurology [Internet]. 2020 Sep [cited 2024 Jun 27];331:113379. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014488620302107
  5. Wiedmer P, Jung T, Castro JP, Pomatto LCD, Sun PY, Davies KJA, et al. Sarcopenia – Molecular mechanisms and open questions. Ageing Research Reviews [Internet]. 2021 Jan [cited 2024 Jun 27];65:101200. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1568163720303354
  6. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. J Biosci [Internet]. 2006 Mar [cited 2024 Jun 27];31(1):137–55. Available from: http://link.springer.com/10.1007/BF02705243
  7. Xiong Y, Yu C, Zhang Q. Ubiquitin-proteasome system–regulated protein degradation in spermatogenesis. Cells [Internet]. 2022 Mar 21 [cited 2024 Jun 27];11(6):1058. Available from: https://www.mdpi.com/2073-4409/11/6/1058
  8. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell [Internet]. 2011 Nov [cited 2024 Jun 27];147(4):728–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867411012761
  9. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest [Internet]. 2000 Apr [cited 2024 Jun 27];117(4):1162–72. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0012369215328208
  10. Cho MR, Lee S, Song SK. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci [Internet]. 2022 [cited 2024 Jun 27];37(18):e146. Available from: https://jkms.org/DOIx.php?id=10.3346/jkms.2022.37.e146

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative
[optin-monster-inline slug="yw0fgpzdy6fjeb0bbekx"]
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Binitaben Bijalkumar Patel

Master of Drug Discovery and Toxicology - MSc, University of Hertfordshire, England

Binita is a Clinical Contract Analyst with a distinguished background in the pharmaceutical industry, specializing in contracts for oncology clinical trials. Her expertise spans across various phases of clinical trials, from early-stage studies to late-phase studies, ensuring that new trials are set up efficiently across many countries. Binita's comprehensive knowledge of regulatory requirements and her adeptness in navigating complex clinical landscapes have been instrumental in the successful execution of many contracts. Her work is characterised by her commitment to precision and her collaborative approach. With a keen eye for detail and a deep understanding of the intricacies of oncology, Binita continues to drive progress in the pharmaceutical industry.

my.klarity.health presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Email:
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818
arrow-right